Alkermes PLC (NASDAQ: ALKS) saw its stock price surge 5.02% in intraday trading on Thursday, as the biopharmaceutical company's strong financial performance and positive outlook fueled investor optimism.
The company reported robust fiscal year 2024 results, with total revenue exceeding $1.5 billion, driven by its proprietary commercial portfolio. Notably, Alkermes achieved over $450 million in EBITDA from continuing operations and ended the year debt-free with a solid cash position of $825 million.
Key products like VIVITROL, ARISTADA, and LYBALVI demonstrated growth, with LYBALVI's net sales increasing by an impressive 46% year-over-year in 2024. Moreover, Alkermes is expanding its psychiatry sales team by approximately 80 representatives to maintain a strong competitive position in the market.
Investors are also optimistic about Alkermes' pipeline candidate ALKS 2680 for narcolepsy, which showed promising results in Phase Ib trials. The company plans to pursue accelerated pathways to market after completing the ongoing Phase II studies and meeting with regulatory authorities.
Several analysts have maintained positive ratings and price targets on Alkermes, citing the company's underlying strength and favorable outlook. H.C. Wainwright, for instance, reiterated a Neutral rating with a $46 price target, while Mizuho Securities maintained a Buy rating following the Q4 2024 earnings report.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。